nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Vandetanib—thyroid cancer	0.293	1	CrCtD
Bosutinib—Protein Kinase Inhibitors—Vandetanib—thyroid cancer	0.285	1	CiPCiCtD
Bosutinib—Gefitinib—Vandetanib—thyroid cancer	0.136	1	CrCrCtD
Bosutinib—AXL—Vandetanib—thyroid cancer	0.0101	0.0504	CbGbCtD
Bosutinib—EPHA5—Vandetanib—thyroid cancer	0.0101	0.0504	CbGbCtD
Bosutinib—ERBB3—Vandetanib—thyroid cancer	0.0101	0.0504	CbGbCtD
Bosutinib—IRAK4—Vandetanib—thyroid cancer	0.0101	0.0504	CbGbCtD
Bosutinib—FYN—Vandetanib—thyroid cancer	0.0101	0.0504	CbGbCtD
Bosutinib—STK35—Vandetanib—thyroid cancer	0.0101	0.0504	CbGbCtD
Bosutinib—TYRO3—Vandetanib—thyroid cancer	0.0101	0.0504	CbGbCtD
Bosutinib—YES1—Vandetanib—thyroid cancer	0.00844	0.0422	CbGbCtD
Bosutinib—MAP4K5—Vandetanib—thyroid cancer	0.00844	0.0422	CbGbCtD
Bosutinib—EPHA8—Vandetanib—thyroid cancer	0.00844	0.0422	CbGbCtD
Bosutinib—SLK—Vandetanib—thyroid cancer	0.00844	0.0422	CbGbCtD
Bosutinib—FGR—Vandetanib—thyroid cancer	0.0073	0.0364	CbGbCtD
Bosutinib—LYN—Vandetanib—thyroid cancer	0.00645	0.0322	CbGbCtD
Bosutinib—BLK—Vandetanib—thyroid cancer	0.00645	0.0322	CbGbCtD
Bosutinib—SRC—Vandetanib—thyroid cancer	0.00645	0.0322	CbGbCtD
Bosutinib—MAP3K7—Sorafenib—thyroid cancer	0.00608	0.0304	CbGbCtD
Bosutinib—EGFR—Vandetanib—thyroid cancer	0.0058	0.0289	CbGbCtD
Bosutinib—ABL2—Vandetanib—thyroid cancer	0.0058	0.0289	CbGbCtD
Bosutinib—STK10—Vandetanib—thyroid cancer	0.0058	0.0289	CbGbCtD
Bosutinib—MAP2K5—Vandetanib—thyroid cancer	0.00528	0.0263	CbGbCtD
Bosutinib—LCK—Vandetanib—thyroid cancer	0.00528	0.0263	CbGbCtD
Bosutinib—PDGFRB—Vandetanib—thyroid cancer	0.00528	0.0263	CbGbCtD
Bosutinib—MAP3K19—Vandetanib—thyroid cancer	0.00485	0.0242	CbGbCtD
Bosutinib—ABL1—Vandetanib—thyroid cancer	0.00419	0.0209	CbGbCtD
Bosutinib—HIPK4—Sorafenib—thyroid cancer	0.00389	0.0194	CbGbCtD
Bosutinib—CSF1R—Sorafenib—thyroid cancer	0.00349	0.0174	CbGbCtD
Bosutinib—STK10—Sorafenib—thyroid cancer	0.00349	0.0174	CbGbCtD
Bosutinib—MAP2K5—Sorafenib—thyroid cancer	0.00318	0.0159	CbGbCtD
Bosutinib—PDGFRB—Sorafenib—thyroid cancer	0.00318	0.0159	CbGbCtD
Bosutinib—MAP3K19—Sorafenib—thyroid cancer	0.00292	0.0146	CbGbCtD
Bosutinib—Vandetanib—RET—thyroid cancer	0.000646	1	CrCbGaD
Bosutinib—STK25—Afatinib—Vandetanib—thyroid cancer	0.000212	0.26	CbGdCrCtD
Bosutinib—ABCB1—Sorafenib—thyroid cancer	0.000208	0.00104	CbGbCtD
Bosutinib—CYP3A4—Vandetanib—thyroid cancer	0.000207	0.00103	CbGbCtD
Bosutinib—PKMYT1—Afatinib—Vandetanib—thyroid cancer	0.000168	0.206	CbGdCrCtD
Bosutinib—ABCB1—Doxorubicin—thyroid cancer	0.000126	0.00063	CbGbCtD
Bosutinib—Renal failure acute—Sorafenib—thyroid cancer	0.000126	0.00581	CcSEcCtD
Bosutinib—Hepatobiliary disease—Vandetanib—thyroid cancer	0.000126	0.0058	CcSEcCtD
Bosutinib—CYP3A4—Sorafenib—thyroid cancer	0.000125	0.000622	CbGbCtD
Bosutinib—Urinary tract disorder—Vandetanib—thyroid cancer	0.000118	0.00543	CcSEcCtD
Bosutinib—Urethral disorder—Vandetanib—thyroid cancer	0.000117	0.00539	CcSEcCtD
Bosutinib—Myelosuppression—Doxorubicin—thyroid cancer	0.000117	0.00539	CcSEcCtD
Bosutinib—Erythema multiforme—Vandetanib—thyroid cancer	0.000113	0.0052	CcSEcCtD
Bosutinib—Cardiac disorder—Vandetanib—thyroid cancer	0.000111	0.00511	CcSEcCtD
Bosutinib—Dehydration—Sorafenib—thyroid cancer	0.000108	0.00499	CcSEcCtD
Bosutinib—Mediastinal disorder—Vandetanib—thyroid cancer	0.000107	0.00496	CcSEcCtD
Bosutinib—Abdominal pain upper—Sorafenib—thyroid cancer	0.000106	0.0049	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.000105	0.00483	CcSEcCtD
Bosutinib—Nasopharyngitis—Sorafenib—thyroid cancer	0.000104	0.0048	CcSEcCtD
Bosutinib—Malnutrition—Vandetanib—thyroid cancer	0.000104	0.00479	CcSEcCtD
Bosutinib—Gastritis—Sorafenib—thyroid cancer	0.000103	0.00475	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.000103	0.00473	CcSEcCtD
Bosutinib—Hypophosphataemia—Epirubicin—thyroid cancer	0.000102	0.0047	CcSEcCtD
Bosutinib—Dysgeusia—Vandetanib—thyroid cancer	0.000102	0.00469	CcSEcCtD
Bosutinib—Febrile neutropenia—Epirubicin—thyroid cancer	9.84e-05	0.00454	CcSEcCtD
Bosutinib—Abdominal discomfort—Sorafenib—thyroid cancer	9.63e-05	0.00444	CcSEcCtD
Bosutinib—Hypophosphataemia—Doxorubicin—thyroid cancer	9.42e-05	0.00435	CcSEcCtD
Bosutinib—Neutropenia—Sorafenib—thyroid cancer	9.39e-05	0.00433	CcSEcCtD
Bosutinib—PLK2—thyroid gland—thyroid cancer	9.37e-05	0.00386	CbGeAlD
Bosutinib—STK26—head—thyroid cancer	9.35e-05	0.00385	CbGeAlD
Bosutinib—SIK3—thyroid gland—thyroid cancer	9.31e-05	0.00383	CbGeAlD
Bosutinib—MAP4K4—trachea—thyroid cancer	9.24e-05	0.0038	CbGeAlD
Bosutinib—BCR—trachea—thyroid cancer	9.17e-05	0.00378	CbGeAlD
Bosutinib—NUAK2—trachea—thyroid cancer	9.17e-05	0.00378	CbGeAlD
Bosutinib—Febrile neutropenia—Doxorubicin—thyroid cancer	9.1e-05	0.0042	CcSEcCtD
Bosutinib—SLK—saliva-secreting gland—thyroid cancer	9.07e-05	0.00374	CbGeAlD
Bosutinib—Cough—Vandetanib—thyroid cancer	9.06e-05	0.00418	CcSEcCtD
Bosutinib—Pneumonia—Sorafenib—thyroid cancer	9.01e-05	0.00416	CcSEcCtD
Bosutinib—EPHB4—saliva-secreting gland—thyroid cancer	9.01e-05	0.00371	CbGeAlD
Bosutinib—STK4—thyroid gland—thyroid cancer	8.96e-05	0.00369	CbGeAlD
Bosutinib—WEE1—head—thyroid cancer	8.96e-05	0.00369	CbGeAlD
Bosutinib—DMPK—head—thyroid cancer	8.96e-05	0.00369	CbGeAlD
Bosutinib—Infestation—Sorafenib—thyroid cancer	8.96e-05	0.00413	CcSEcCtD
Bosutinib—Infestation NOS—Sorafenib—thyroid cancer	8.96e-05	0.00413	CcSEcCtD
Bosutinib—CSK—trachea—thyroid cancer	8.86e-05	0.00365	CbGeAlD
Bosutinib—CAMK1D—thyroid gland—thyroid cancer	8.86e-05	0.00365	CbGeAlD
Bosutinib—EPHA2—saliva-secreting gland—thyroid cancer	8.84e-05	0.00364	CbGeAlD
Bosutinib—Chest pain—Vandetanib—thyroid cancer	8.83e-05	0.00408	CcSEcCtD
Bosutinib—Arthralgia—Vandetanib—thyroid cancer	8.83e-05	0.00408	CcSEcCtD
Bosutinib—Renal failure—Sorafenib—thyroid cancer	8.81e-05	0.00406	CcSEcCtD
Bosutinib—CSNK1A1—trachea—thyroid cancer	8.8e-05	0.00363	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	8.77e-05	0.00405	CcSEcCtD
Bosutinib—STK24—thyroid gland—thyroid cancer	8.75e-05	0.0036	CbGeAlD
Bosutinib—CLK1—trachea—thyroid cancer	8.75e-05	0.0036	CbGeAlD
Bosutinib—HCK—trachea—thyroid cancer	8.75e-05	0.0036	CbGeAlD
Bosutinib—MAP4K5—saliva-secreting gland—thyroid cancer	8.62e-05	0.00355	CbGeAlD
Bosutinib—MAP3K3—saliva-secreting gland—thyroid cancer	8.62e-05	0.00355	CbGeAlD
Bosutinib—STK25—head—thyroid cancer	8.55e-05	0.00352	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—thyroid cancer	8.53e-05	0.105	CbGdCrCtD
Bosutinib—EPHA3—head—thyroid cancer	8.49e-05	0.0035	CbGeAlD
Bosutinib—Hepatobiliary disease—Sorafenib—thyroid cancer	8.47e-05	0.00391	CcSEcCtD
Bosutinib—FER—thyroid gland—thyroid cancer	8.47e-05	0.00349	CbGeAlD
Bosutinib—Oedema—Vandetanib—thyroid cancer	8.47e-05	0.00391	CcSEcCtD
Bosutinib—Infection—Vandetanib—thyroid cancer	8.41e-05	0.00388	CcSEcCtD
Bosutinib—PLK2—head—thyroid cancer	8.32e-05	0.00342	CbGeAlD
Bosutinib—Nervous system disorder—Vandetanib—thyroid cancer	8.31e-05	0.00383	CcSEcCtD
Bosutinib—MAP4K1—thyroid gland—thyroid cancer	8.3e-05	0.00342	CbGeAlD
Bosutinib—Thrombocytopenia—Vandetanib—thyroid cancer	8.29e-05	0.00383	CcSEcCtD
Bosutinib—SIK3—head—thyroid cancer	8.26e-05	0.0034	CbGeAlD
Bosutinib—BTK—thyroid gland—thyroid cancer	8.26e-05	0.0034	CbGeAlD
Bosutinib—Skin disorder—Vandetanib—thyroid cancer	8.23e-05	0.0038	CcSEcCtD
Bosutinib—CSNK1E—trachea—thyroid cancer	8.16e-05	0.00336	CbGeAlD
Bosutinib—TNK2—thyroid gland—thyroid cancer	8.14e-05	0.00335	CbGeAlD
Bosutinib—IRAK4—trachea—thyroid cancer	8.03e-05	0.00331	CbGeAlD
Bosutinib—MAP4K2—thyroid gland—thyroid cancer	8.03e-05	0.0033	CbGeAlD
Bosutinib—YES1—saliva-secreting gland—thyroid cancer	7.96e-05	0.00328	CbGeAlD
Bosutinib—STK4—head—thyroid cancer	7.95e-05	0.00327	CbGeAlD
Bosutinib—EPHA4—trachea—thyroid cancer	7.95e-05	0.00327	CbGeAlD
Bosutinib—Urinary tract disorder—Sorafenib—thyroid cancer	7.94e-05	0.00366	CcSEcCtD
Bosutinib—STK3—thyroid gland—thyroid cancer	7.92e-05	0.00326	CbGeAlD
Bosutinib—ERBB4—thyroid gland—thyroid cancer	7.92e-05	0.00326	CbGeAlD
Bosutinib—Connective tissue disorder—Sorafenib—thyroid cancer	7.9e-05	0.00365	CcSEcCtD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—thyroid cancer	7.9e-05	0.0968	CbGdCrCtD
Bosutinib—Urethral disorder—Sorafenib—thyroid cancer	7.88e-05	0.00364	CcSEcCtD
Bosutinib—ERBB3—trachea—thyroid cancer	7.87e-05	0.00324	CbGeAlD
Bosutinib—TAOK3—saliva-secreting gland—thyroid cancer	7.86e-05	0.00324	CbGeAlD
Bosutinib—CAMK1D—head—thyroid cancer	7.86e-05	0.00324	CbGeAlD
Bosutinib—ULK3—trachea—thyroid cancer	7.85e-05	0.00323	CbGeAlD
Bosutinib—TLK1—lymph node—thyroid cancer	7.85e-05	0.00323	CbGeAlD
Bosutinib—PDGFRB—neck—thyroid cancer	7.82e-05	0.00322	CbGeAlD
Bosutinib—STK24—head—thyroid cancer	7.77e-05	0.0032	CbGeAlD
Bosutinib—PRKCQ—lymph node—thyroid cancer	7.74e-05	0.00319	CbGeAlD
Bosutinib—Pleural effusion—Epirubicin—thyroid cancer	7.73e-05	0.00357	CcSEcCtD
Bosutinib—MAP3K7—trachea—thyroid cancer	7.72e-05	0.00318	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Vandetanib—thyroid cancer	7.72e-05	0.00356	CcSEcCtD
Bosutinib—PTK2—trachea—thyroid cancer	7.64e-05	0.00314	CbGeAlD
Bosutinib—TBK1—trachea—thyroid cancer	7.64e-05	0.00314	CbGeAlD
Bosutinib—Erythema multiforme—Sorafenib—thyroid cancer	7.6e-05	0.00351	CcSEcCtD
Bosutinib—BMPR2—thyroid gland—thyroid cancer	7.59e-05	0.00313	CbGeAlD
Bosutinib—CYP3A4—Doxorubicin—thyroid cancer	7.56e-05	0.000378	CbGbCtD
Bosutinib—Dyspnoea—Vandetanib—thyroid cancer	7.55e-05	0.00348	CcSEcCtD
Bosutinib—STK36—thyroid gland—thyroid cancer	7.53e-05	0.0031	CbGeAlD
Bosutinib—TYRO3—head—thyroid cancer	7.52e-05	0.00309	CbGeAlD
Bosutinib—FER—head—thyroid cancer	7.52e-05	0.00309	CbGeAlD
Bosutinib—EPHA5—head—thyroid cancer	7.52e-05	0.00309	CbGeAlD
Bosutinib—ALK—head—thyroid cancer	7.52e-05	0.00309	CbGeAlD
Bosutinib—Tinnitus—Sorafenib—thyroid cancer	7.5e-05	0.00346	CcSEcCtD
Bosutinib—LYN—head—thyroid cancer	7.48e-05	0.00308	CbGeAlD
Bosutinib—Cardiac disorder—Sorafenib—thyroid cancer	7.46e-05	0.00344	CcSEcCtD
Bosutinib—MERTK—thyroid gland—thyroid cancer	7.44e-05	0.00307	CbGeAlD
Bosutinib—MAP3K19—head—thyroid cancer	7.36e-05	0.00303	CbGeAlD
Bosutinib—Decreased appetite—Vandetanib—thyroid cancer	7.36e-05	0.0034	CcSEcCtD
Bosutinib—RPS6KB1—trachea—thyroid cancer	7.35e-05	0.00302	CbGeAlD
Bosutinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	7.31e-05	0.00337	CcSEcCtD
Bosutinib—MAP4K4—thyroid gland—thyroid cancer	7.31e-05	0.00301	CbGeAlD
Bosutinib—Fatigue—Vandetanib—thyroid cancer	7.3e-05	0.00337	CcSEcCtD
Bosutinib—LCK—trachea—thyroid cancer	7.3e-05	0.00301	CbGeAlD
Bosutinib—AXL—trachea—thyroid cancer	7.27e-05	0.00299	CbGeAlD
Bosutinib—Immune system disorder—Sorafenib—thyroid cancer	7.26e-05	0.00335	CcSEcCtD
Bosutinib—DSTYK—lymph node—thyroid cancer	7.26e-05	0.00299	CbGeAlD
Bosutinib—BMX—lymph node—thyroid cancer	7.26e-05	0.00299	CbGeAlD
Bosutinib—CLK3—lymph node—thyroid cancer	7.26e-05	0.00299	CbGeAlD
Bosutinib—NUAK2—thyroid gland—thyroid cancer	7.25e-05	0.00299	CbGeAlD
Bosutinib—BCR—thyroid gland—thyroid cancer	7.25e-05	0.00299	CbGeAlD
Bosutinib—Mediastinal disorder—Sorafenib—thyroid cancer	7.25e-05	0.00334	CcSEcCtD
Bosutinib—Pain—Vandetanib—thyroid cancer	7.24e-05	0.00334	CcSEcCtD
Bosutinib—TNK2—head—thyroid cancer	7.22e-05	0.00297	CbGeAlD
Bosutinib—MAP3K12—thyroid gland—thyroid cancer	7.2e-05	0.00297	CbGeAlD
Bosutinib—BLK—lymph node—thyroid cancer	7.18e-05	0.00295	CbGeAlD
Bosutinib—Pleural effusion—Doxorubicin—thyroid cancer	7.15e-05	0.0033	CcSEcCtD
Bosutinib—CASK—lymph node—thyroid cancer	7.1e-05	0.00292	CbGeAlD
Bosutinib—PHKG1—lymph node—thyroid cancer	7.1e-05	0.00292	CbGeAlD
Bosutinib—STK35—thyroid gland—thyroid cancer	7.06e-05	0.00291	CbGeAlD
Bosutinib—MAP2K5—saliva-secreting gland—thyroid cancer	7.05e-05	0.0029	CbGeAlD
Bosutinib—Liver injury—Epirubicin—thyroid cancer	7.03e-05	0.00325	CcSEcCtD
Bosutinib—ERBB4—head—thyroid cancer	7.02e-05	0.00289	CbGeAlD
Bosutinib—STK3—head—thyroid cancer	7.02e-05	0.00289	CbGeAlD
Bosutinib—EIF2AK1—lymph node—thyroid cancer	7.02e-05	0.00289	CbGeAlD
Bosutinib—CSK—thyroid gland—thyroid cancer	7.01e-05	0.00289	CbGeAlD
Bosutinib—Malnutrition—Sorafenib—thyroid cancer	7e-05	0.00323	CcSEcCtD
Bosutinib—SLK—trachea—thyroid cancer	7e-05	0.00288	CbGeAlD
Bosutinib—CSNK1A1—thyroid gland—thyroid cancer	6.97e-05	0.00287	CbGeAlD
Bosutinib—EPHB4—trachea—thyroid cancer	6.95e-05	0.00286	CbGeAlD
Bosutinib—ROCK1—head—thyroid cancer	6.93e-05	0.00285	CbGeAlD
Bosutinib—Gastrointestinal pain—Vandetanib—thyroid cancer	6.93e-05	0.0032	CcSEcCtD
Bosutinib—CLK1—thyroid gland—thyroid cancer	6.92e-05	0.00285	CbGeAlD
Bosutinib—HCK—thyroid gland—thyroid cancer	6.92e-05	0.00285	CbGeAlD
Bosutinib—ABL2—thyroid gland—thyroid cancer	6.88e-05	0.00283	CbGeAlD
Bosutinib—TXK—lymph node—thyroid cancer	6.87e-05	0.00283	CbGeAlD
Bosutinib—Dysgeusia—Sorafenib—thyroid cancer	6.86e-05	0.00316	CcSEcCtD
Bosutinib—EPHA2—trachea—thyroid cancer	6.82e-05	0.00281	CbGeAlD
Bosutinib—FYN—trachea—thyroid cancer	6.81e-05	0.0028	CbGeAlD
Bosutinib—FES—lymph node—thyroid cancer	6.8e-05	0.0028	CbGeAlD
Bosutinib—VRK2—lymph node—thyroid cancer	6.8e-05	0.0028	CbGeAlD
Bosutinib—CAMK2G—thyroid gland—thyroid cancer	6.79e-05	0.0028	CbGeAlD
Bosutinib—BMP2K—thyroid gland—thyroid cancer	6.79e-05	0.0028	CbGeAlD
Bosutinib—BMPR2—head—thyroid cancer	6.73e-05	0.00277	CbGeAlD
Bosutinib—LRRK2—thyroid gland—thyroid cancer	6.73e-05	0.00277	CbGeAlD
Bosutinib—EGFR—thyroid gland—thyroid cancer	6.71e-05	0.00276	CbGeAlD
Bosutinib—Abdominal pain—Vandetanib—thyroid cancer	6.7e-05	0.00309	CcSEcCtD
Bosutinib—Body temperature increased—Vandetanib—thyroid cancer	6.7e-05	0.00309	CcSEcCtD
Bosutinib—EPHB3—head—thyroid cancer	6.68e-05	0.00275	CbGeAlD
Bosutinib—STK36—head—thyroid cancer	6.68e-05	0.00275	CbGeAlD
Bosutinib—TNIK—lymph node—thyroid cancer	6.67e-05	0.00275	CbGeAlD
Bosutinib—SYK—lymph node—thyroid cancer	6.67e-05	0.00275	CbGeAlD
Bosutinib—MAP3K3—trachea—thyroid cancer	6.65e-05	0.00274	CbGeAlD
Bosutinib—MAP4K5—trachea—thyroid cancer	6.65e-05	0.00274	CbGeAlD
Bosutinib—CDK2—lymph node—thyroid cancer	6.61e-05	0.00272	CbGeAlD
Bosutinib—MERTK—head—thyroid cancer	6.6e-05	0.00272	CbGeAlD
Bosutinib—PTK2B—thyroid gland—thyroid cancer	6.56e-05	0.0027	CbGeAlD
Bosutinib—STK26—lymph node—thyroid cancer	6.55e-05	0.0027	CbGeAlD
Bosutinib—Liver injury—Doxorubicin—thyroid cancer	6.51e-05	0.003	CcSEcCtD
Bosutinib—MAP4K4—head—thyroid cancer	6.48e-05	0.00267	CbGeAlD
Bosutinib—Anaemia—Sorafenib—thyroid cancer	6.47e-05	0.00299	CcSEcCtD
Bosutinib—CSNK1E—thyroid gland—thyroid cancer	6.45e-05	0.00266	CbGeAlD
Bosutinib—BCR—head—thyroid cancer	6.44e-05	0.00265	CbGeAlD
Bosutinib—MAP3K12—head—thyroid cancer	6.39e-05	0.00263	CbGeAlD
Bosutinib—SIK1—thyroid gland—thyroid cancer	6.35e-05	0.00262	CbGeAlD
Bosutinib—IRAK4—thyroid gland—thyroid cancer	6.35e-05	0.00262	CbGeAlD
Bosutinib—CHEK2—lymph node—thyroid cancer	6.32e-05	0.0026	CbGeAlD
Bosutinib—EPHA4—thyroid gland—thyroid cancer	6.29e-05	0.00259	CbGeAlD
Bosutinib—DMPK—lymph node—thyroid cancer	6.27e-05	0.00258	CbGeAlD
Bosutinib—WEE1—lymph node—thyroid cancer	6.27e-05	0.00258	CbGeAlD
Bosutinib—Leukopenia—Sorafenib—thyroid cancer	6.27e-05	0.00289	CcSEcCtD
Bosutinib—MAP2K1—head—thyroid cancer	6.26e-05	0.00258	CbGeAlD
Bosutinib—STK35—head—thyroid cancer	6.26e-05	0.00258	CbGeAlD
Bosutinib—Blood bilirubin increased—Epirubicin—thyroid cancer	6.26e-05	0.00289	CcSEcCtD
Bosutinib—ERBB3—thyroid gland—thyroid cancer	6.23e-05	0.00256	CbGeAlD
Bosutinib—CSK—head—thyroid cancer	6.22e-05	0.00256	CbGeAlD
Bosutinib—ULK3—thyroid gland—thyroid cancer	6.21e-05	0.00256	CbGeAlD
Bosutinib—MAP2K2—thyroid gland—thyroid cancer	6.21e-05	0.00256	CbGeAlD
Bosutinib—CSNK1A1—head—thyroid cancer	6.18e-05	0.00254	CbGeAlD
Bosutinib—MAP3K2—thyroid gland—thyroid cancer	6.17e-05	0.00254	CbGeAlD
Bosutinib—YES1—trachea—thyroid cancer	6.14e-05	0.00253	CbGeAlD
Bosutinib—CLK1—head—thyroid cancer	6.14e-05	0.00253	CbGeAlD
Bosutinib—HCK—head—thyroid cancer	6.14e-05	0.00253	CbGeAlD
Bosutinib—MAP3K7—thyroid gland—thyroid cancer	6.11e-05	0.00252	CbGeAlD
Bosutinib—Cough—Sorafenib—thyroid cancer	6.11e-05	0.00282	CcSEcCtD
Bosutinib—PDGFRB—saliva-secreting gland—thyroid cancer	6.1e-05	0.00251	CbGeAlD
Bosutinib—Asthenia—Vandetanib—thyroid cancer	6.08e-05	0.0028	CcSEcCtD
Bosutinib—TAOK3—trachea—thyroid cancer	6.06e-05	0.0025	CbGeAlD
Bosutinib—PTK2—thyroid gland—thyroid cancer	6.04e-05	0.00249	CbGeAlD
Bosutinib—TBK1—thyroid gland—thyroid cancer	6.04e-05	0.00249	CbGeAlD
Bosutinib—CAMK2G—head—thyroid cancer	6.03e-05	0.00248	CbGeAlD
Bosutinib—BMP2K—head—thyroid cancer	6.03e-05	0.00248	CbGeAlD
Bosutinib—Pruritus—Vandetanib—thyroid cancer	5.99e-05	0.00276	CcSEcCtD
Bosutinib—STK25—lymph node—thyroid cancer	5.99e-05	0.00247	CbGeAlD
Bosutinib—LRRK2—head—thyroid cancer	5.97e-05	0.00246	CbGeAlD
Bosutinib—Myalgia—Sorafenib—thyroid cancer	5.96e-05	0.00275	CcSEcCtD
Bosutinib—Arthralgia—Sorafenib—thyroid cancer	5.96e-05	0.00275	CcSEcCtD
Bosutinib—EPHA3—lymph node—thyroid cancer	5.95e-05	0.00245	CbGeAlD
Bosutinib—IRAK1—thyroid gland—thyroid cancer	5.92e-05	0.00244	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	5.92e-05	0.00273	CcSEcCtD
Bosutinib—PLK2—lymph node—thyroid cancer	5.82e-05	0.0024	CbGeAlD
Bosutinib—PTK2B—head—thyroid cancer	5.82e-05	0.0024	CbGeAlD
Bosutinib—Hyperkalaemia—Epirubicin—thyroid cancer	5.81e-05	0.00268	CcSEcCtD
Bosutinib—RPS6KB1—thyroid gland—thyroid cancer	5.81e-05	0.00239	CbGeAlD
Bosutinib—Diarrhoea—Vandetanib—thyroid cancer	5.79e-05	0.00267	CcSEcCtD
Bosutinib—Blood bilirubin increased—Doxorubicin—thyroid cancer	5.79e-05	0.00267	CcSEcCtD
Bosutinib—SIK3—lymph node—thyroid cancer	5.78e-05	0.00238	CbGeAlD
Bosutinib—FGR—thyroid gland—thyroid cancer	5.78e-05	0.00238	CbGeAlD
Bosutinib—LCK—thyroid gland—thyroid cancer	5.78e-05	0.00238	CbGeAlD
Bosutinib—AXL—thyroid gland—thyroid cancer	5.75e-05	0.00237	CbGeAlD
Bosutinib—CSNK1E—head—thyroid cancer	5.73e-05	0.00236	CbGeAlD
Bosutinib—Anaphylactic shock—Sorafenib—thyroid cancer	5.71e-05	0.00264	CcSEcCtD
Bosutinib—Infection—Sorafenib—thyroid cancer	5.68e-05	0.00262	CcSEcCtD
Bosutinib—SIK1—head—thyroid cancer	5.64e-05	0.00232	CbGeAlD
Bosutinib—IRAK4—head—thyroid cancer	5.64e-05	0.00232	CbGeAlD
Bosutinib—Fluid retention—Epirubicin—thyroid cancer	5.62e-05	0.00259	CcSEcCtD
Bosutinib—Nervous system disorder—Sorafenib—thyroid cancer	5.6e-05	0.00259	CcSEcCtD
Bosutinib—Dizziness—Vandetanib—thyroid cancer	5.6e-05	0.00258	CcSEcCtD
Bosutinib—Thrombocytopenia—Sorafenib—thyroid cancer	5.59e-05	0.00258	CcSEcCtD
Bosutinib—EPHA4—head—thyroid cancer	5.58e-05	0.0023	CbGeAlD
Bosutinib—STK4—lymph node—thyroid cancer	5.57e-05	0.00229	CbGeAlD
Bosutinib—Skin disorder—Sorafenib—thyroid cancer	5.55e-05	0.00256	CcSEcCtD
Bosutinib—SLK—thyroid gland—thyroid cancer	5.54e-05	0.00228	CbGeAlD
Bosutinib—ERBB3—head—thyroid cancer	5.53e-05	0.00228	CbGeAlD
Bosutinib—ULK3—head—thyroid cancer	5.51e-05	0.00227	CbGeAlD
Bosutinib—MAP2K2—head—thyroid cancer	5.51e-05	0.00227	CbGeAlD
Bosutinib—CAMK1D—lymph node—thyroid cancer	5.5e-05	0.00227	CbGeAlD
Bosutinib—EPHB4—thyroid gland—thyroid cancer	5.5e-05	0.00226	CbGeAlD
Bosutinib—MAP3K2—head—thyroid cancer	5.47e-05	0.00225	CbGeAlD
Bosutinib—STK24—lymph node—thyroid cancer	5.44e-05	0.00224	CbGeAlD
Bosutinib—ABL1—saliva-secreting gland—thyroid cancer	5.44e-05	0.00224	CbGeAlD
Bosutinib—MAP2K5—trachea—thyroid cancer	5.44e-05	0.00224	CbGeAlD
Bosutinib—EPHA2—thyroid gland—thyroid cancer	5.39e-05	0.00222	CbGeAlD
Bosutinib—Vomiting—Vandetanib—thyroid cancer	5.38e-05	0.00248	CcSEcCtD
Bosutinib—FYN—thyroid gland—thyroid cancer	5.38e-05	0.00222	CbGeAlD
Bosutinib—Hyperkalaemia—Doxorubicin—thyroid cancer	5.38e-05	0.00248	CcSEcCtD
Bosutinib—Rash maculo-papular—Epirubicin—thyroid cancer	5.38e-05	0.00248	CcSEcCtD
Bosutinib—PTK2—head—thyroid cancer	5.36e-05	0.00221	CbGeAlD
Bosutinib—TBK1—head—thyroid cancer	5.36e-05	0.00221	CbGeAlD
Bosutinib—Rash—Vandetanib—thyroid cancer	5.34e-05	0.00246	CcSEcCtD
Bosutinib—Dermatitis—Vandetanib—thyroid cancer	5.34e-05	0.00246	CcSEcCtD
Bosutinib—Headache—Vandetanib—thyroid cancer	5.31e-05	0.00245	CcSEcCtD
Bosutinib—CSF1R—trachea—thyroid cancer	5.31e-05	0.00218	CbGeAlD
Bosutinib—FER—lymph node—thyroid cancer	5.26e-05	0.00217	CbGeAlD
Bosutinib—ALK—lymph node—thyroid cancer	5.26e-05	0.00217	CbGeAlD
Bosutinib—MAP3K3—thyroid gland—thyroid cancer	5.26e-05	0.00217	CbGeAlD
Bosutinib—MAP4K5—thyroid gland—thyroid cancer	5.26e-05	0.00217	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	5.21e-05	0.0024	CcSEcCtD
Bosutinib—Fluid retention—Doxorubicin—thyroid cancer	5.2e-05	0.0024	CcSEcCtD
Bosutinib—MAP4K1—lymph node—thyroid cancer	5.16e-05	0.00212	CbGeAlD
Bosutinib—RPS6KB1—head—thyroid cancer	5.16e-05	0.00212	CbGeAlD
Bosutinib—BTK—lymph node—thyroid cancer	5.13e-05	0.00211	CbGeAlD
Bosutinib—FGR—head—thyroid cancer	5.12e-05	0.00211	CbGeAlD
Bosutinib—AXL—head—thyroid cancer	5.1e-05	0.0021	CbGeAlD
Bosutinib—Dyspnoea—Sorafenib—thyroid cancer	5.09e-05	0.00235	CcSEcCtD
Bosutinib—TNK2—lymph node—thyroid cancer	5.06e-05	0.00208	CbGeAlD
Bosutinib—Nausea—Vandetanib—thyroid cancer	5.03e-05	0.00232	CcSEcCtD
Bosutinib—MAP4K2—lymph node—thyroid cancer	4.99e-05	0.00205	CbGeAlD
Bosutinib—Rash maculo-papular—Doxorubicin—thyroid cancer	4.98e-05	0.0023	CcSEcCtD
Bosutinib—Decreased appetite—Sorafenib—thyroid cancer	4.97e-05	0.00229	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	4.93e-05	0.00228	CcSEcCtD
Bosutinib—Fatigue—Sorafenib—thyroid cancer	4.93e-05	0.00227	CcSEcCtD
Bosutinib—STK3—lymph node—thyroid cancer	4.92e-05	0.00203	CbGeAlD
Bosutinib—Hepatic function abnormal—Epirubicin—thyroid cancer	4.92e-05	0.00227	CcSEcCtD
Bosutinib—Pain—Sorafenib—thyroid cancer	4.89e-05	0.00225	CcSEcCtD
Bosutinib—YES1—thyroid gland—thyroid cancer	4.86e-05	0.002	CbGeAlD
Bosutinib—STK10—thyroid gland—thyroid cancer	4.82e-05	0.00198	CbGeAlD
Bosutinib—TAOK3—thyroid gland—thyroid cancer	4.8e-05	0.00198	CbGeAlD
Bosutinib—EPHA2—head—thyroid cancer	4.78e-05	0.00197	CbGeAlD
Bosutinib—FYN—head—thyroid cancer	4.78e-05	0.00197	CbGeAlD
Bosutinib—BMPR2—lymph node—thyroid cancer	4.72e-05	0.00194	CbGeAlD
Bosutinib—PDGFRB—trachea—thyroid cancer	4.7e-05	0.00194	CbGeAlD
Bosutinib—STK36—lymph node—thyroid cancer	4.68e-05	0.00193	CbGeAlD
Bosutinib—EPHB3—lymph node—thyroid cancer	4.68e-05	0.00193	CbGeAlD
Bosutinib—SRC—thyroid gland—thyroid cancer	4.67e-05	0.00192	CbGeAlD
Bosutinib—Gastrointestinal pain—Sorafenib—thyroid cancer	4.67e-05	0.00216	CcSEcCtD
Bosutinib—MAP3K3—head—thyroid cancer	4.67e-05	0.00192	CbGeAlD
Bosutinib—MAP4K5—head—thyroid cancer	4.67e-05	0.00192	CbGeAlD
Bosutinib—Renal failure acute—Epirubicin—thyroid cancer	4.65e-05	0.00215	CcSEcCtD
Bosutinib—MERTK—lymph node—thyroid cancer	4.62e-05	0.0019	CbGeAlD
Bosutinib—Hepatic function abnormal—Doxorubicin—thyroid cancer	4.55e-05	0.0021	CcSEcCtD
Bosutinib—MAP4K4—lymph node—thyroid cancer	4.54e-05	0.00187	CbGeAlD
Bosutinib—Urticaria—Sorafenib—thyroid cancer	4.54e-05	0.00209	CcSEcCtD
Bosutinib—Abdominal pain—Sorafenib—thyroid cancer	4.52e-05	0.00208	CcSEcCtD
Bosutinib—Body temperature increased—Sorafenib—thyroid cancer	4.52e-05	0.00208	CcSEcCtD
Bosutinib—Renal impairment—Epirubicin—thyroid cancer	4.51e-05	0.00208	CcSEcCtD
Bosutinib—BCR—lymph node—thyroid cancer	4.51e-05	0.00186	CbGeAlD
Bosutinib—NUAK2—lymph node—thyroid cancer	4.51e-05	0.00186	CbGeAlD
Bosutinib—MAP3K12—lymph node—thyroid cancer	4.47e-05	0.00184	CbGeAlD
Bosutinib—MAP2K1—lymph node—thyroid cancer	4.38e-05	0.00181	CbGeAlD
Bosutinib—STK35—lymph node—thyroid cancer	4.38e-05	0.00181	CbGeAlD
Bosutinib—CSK—lymph node—thyroid cancer	4.35e-05	0.00179	CbGeAlD
Bosutinib—CSNK1A1—lymph node—thyroid cancer	4.33e-05	0.00178	CbGeAlD
Bosutinib—YES1—head—thyroid cancer	4.31e-05	0.00178	CbGeAlD
Bosutinib—Renal failure acute—Doxorubicin—thyroid cancer	4.31e-05	0.00199	CcSEcCtD
Bosutinib—MAP2K5—thyroid gland—thyroid cancer	4.3e-05	0.00177	CbGeAlD
Bosutinib—HCK—lymph node—thyroid cancer	4.3e-05	0.00177	CbGeAlD
Bosutinib—CLK1—lymph node—thyroid cancer	4.3e-05	0.00177	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	4.3e-05	0.00198	CcSEcCtD
Bosutinib—ABL2—lymph node—thyroid cancer	4.27e-05	0.00176	CbGeAlD
Bosutinib—STK10—head—thyroid cancer	4.27e-05	0.00176	CbGeAlD
Bosutinib—TAOK3—head—thyroid cancer	4.26e-05	0.00175	CbGeAlD
Bosutinib—CAMK2G—lymph node—thyroid cancer	4.22e-05	0.00174	CbGeAlD
Bosutinib—BMP2K—lymph node—thyroid cancer	4.22e-05	0.00174	CbGeAlD
Bosutinib—CSF1R—thyroid gland—thyroid cancer	4.2e-05	0.00173	CbGeAlD
Bosutinib—ABL1—trachea—thyroid cancer	4.19e-05	0.00173	CbGeAlD
Bosutinib—LRRK2—lymph node—thyroid cancer	4.18e-05	0.00172	CbGeAlD
Bosutinib—Renal impairment—Doxorubicin—thyroid cancer	4.18e-05	0.00193	CcSEcCtD
Bosutinib—EGFR—lymph node—thyroid cancer	4.17e-05	0.00172	CbGeAlD
Bosutinib—Face oedema—Epirubicin—thyroid cancer	4.15e-05	0.00191	CcSEcCtD
Bosutinib—SRC—head—thyroid cancer	4.15e-05	0.00171	CbGeAlD
Bosutinib—Asthenia—Sorafenib—thyroid cancer	4.1e-05	0.00189	CcSEcCtD
Bosutinib—PTK2B—lymph node—thyroid cancer	4.08e-05	0.00168	CbGeAlD
Bosutinib—Pruritus—Sorafenib—thyroid cancer	4.04e-05	0.00187	CcSEcCtD
Bosutinib—Blood creatinine increased—Epirubicin—thyroid cancer	4.02e-05	0.00186	CcSEcCtD
Bosutinib—CSNK1E—lymph node—thyroid cancer	4.01e-05	0.00165	CbGeAlD
Bosutinib—Dehydration—Epirubicin—thyroid cancer	4e-05	0.00184	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	3.97e-05	0.00183	CcSEcCtD
Bosutinib—SIK1—lymph node—thyroid cancer	3.95e-05	0.00163	CbGeAlD
Bosutinib—IRAK4—lymph node—thyroid cancer	3.95e-05	0.00163	CbGeAlD
Bosutinib—Abdominal pain upper—Epirubicin—thyroid cancer	3.92e-05	0.00181	CcSEcCtD
Bosutinib—Diarrhoea—Sorafenib—thyroid cancer	3.91e-05	0.0018	CcSEcCtD
Bosutinib—EPHA4—lymph node—thyroid cancer	3.91e-05	0.00161	CbGeAlD
Bosutinib—ERBB3—lymph node—thyroid cancer	3.87e-05	0.00159	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	3.87e-05	0.00179	CcSEcCtD
Bosutinib—MAP2K2—lymph node—thyroid cancer	3.86e-05	0.00159	CbGeAlD
Bosutinib—ULK3—lymph node—thyroid cancer	3.86e-05	0.00159	CbGeAlD
Bosutinib—Nasopharyngitis—Epirubicin—thyroid cancer	3.84e-05	0.00177	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—thyroid cancer	3.84e-05	0.00177	CcSEcCtD
Bosutinib—MAP3K2—lymph node—thyroid cancer	3.83e-05	0.00158	CbGeAlD
Bosutinib—MAP2K5—head—thyroid cancer	3.81e-05	0.00157	CbGeAlD
Bosutinib—Gastritis—Epirubicin—thyroid cancer	3.8e-05	0.00175	CcSEcCtD
Bosutinib—MAP3K7—lymph node—thyroid cancer	3.8e-05	0.00156	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	3.79e-05	0.00175	CcSEcCtD
Bosutinib—Dizziness—Sorafenib—thyroid cancer	3.78e-05	0.00174	CcSEcCtD
Bosutinib—PTK2—lymph node—thyroid cancer	3.75e-05	0.00155	CbGeAlD
Bosutinib—TBK1—lymph node—thyroid cancer	3.75e-05	0.00155	CbGeAlD
Bosutinib—Blood creatinine increased—Doxorubicin—thyroid cancer	3.72e-05	0.00172	CcSEcCtD
Bosutinib—CSF1R—head—thyroid cancer	3.72e-05	0.00153	CbGeAlD
Bosutinib—PDGFRB—thyroid gland—thyroid cancer	3.72e-05	0.00153	CbGeAlD
Bosutinib—Influenza—Epirubicin—thyroid cancer	3.71e-05	0.00171	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—thyroid cancer	3.7e-05	0.00171	CcSEcCtD
Bosutinib—IRAK1—lymph node—thyroid cancer	3.68e-05	0.00151	CbGeAlD
Bosutinib—Vomiting—Sorafenib—thyroid cancer	3.63e-05	0.00168	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—thyroid cancer	3.63e-05	0.00168	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—thyroid cancer	3.61e-05	0.00149	CbGeAlD
Bosutinib—Rash—Sorafenib—thyroid cancer	3.6e-05	0.00166	CcSEcCtD
Bosutinib—Dermatitis—Sorafenib—thyroid cancer	3.6e-05	0.00166	CcSEcCtD
Bosutinib—FGR—lymph node—thyroid cancer	3.59e-05	0.00148	CbGeAlD
Bosutinib—LCK—lymph node—thyroid cancer	3.59e-05	0.00148	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	3.58e-05	0.00165	CcSEcCtD
Bosutinib—Headache—Sorafenib—thyroid cancer	3.58e-05	0.00165	CcSEcCtD
Bosutinib—AXL—lymph node—thyroid cancer	3.57e-05	0.00147	CbGeAlD
Bosutinib—Bronchitis—Epirubicin—thyroid cancer	3.57e-05	0.00165	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—thyroid cancer	3.55e-05	0.00164	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—thyroid cancer	3.53e-05	0.00163	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—thyroid cancer	3.52e-05	0.00162	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	3.51e-05	0.00162	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—thyroid cancer	3.47e-05	0.0016	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—thyroid cancer	3.45e-05	0.00159	CcSEcCtD
Bosutinib—SLK—lymph node—thyroid cancer	3.44e-05	0.00142	CbGeAlD
Bosutinib—Influenza—Doxorubicin—thyroid cancer	3.44e-05	0.00159	CcSEcCtD
Bosutinib—EPHB4—lymph node—thyroid cancer	3.42e-05	0.00141	CbGeAlD
Bosutinib—Nausea—Sorafenib—thyroid cancer	3.39e-05	0.00157	CcSEcCtD
Bosutinib—EPHA2—lymph node—thyroid cancer	3.35e-05	0.00138	CbGeAlD
Bosutinib—FYN—lymph node—thyroid cancer	3.34e-05	0.00138	CbGeAlD
Bosutinib—Pneumonia—Epirubicin—thyroid cancer	3.33e-05	0.00154	CcSEcCtD
Bosutinib—ABL1—thyroid gland—thyroid cancer	3.32e-05	0.00137	CbGeAlD
Bosutinib—Infestation—Epirubicin—thyroid cancer	3.31e-05	0.00153	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—thyroid cancer	3.31e-05	0.00153	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—thyroid cancer	3.3e-05	0.00152	CcSEcCtD
Bosutinib—PDGFRB—head—thyroid cancer	3.3e-05	0.00136	CbGeAlD
Bosutinib—MAP3K3—lymph node—thyroid cancer	3.27e-05	0.00135	CbGeAlD
Bosutinib—MAP4K5—lymph node—thyroid cancer	3.27e-05	0.00135	CbGeAlD
Bosutinib—Pancytopenia—Doxorubicin—thyroid cancer	3.26e-05	0.00151	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—thyroid cancer	3.25e-05	0.0015	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—thyroid cancer	3.21e-05	0.00148	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	3.19e-05	0.00147	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—thyroid cancer	3.13e-05	0.00144	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—thyroid cancer	3.09e-05	0.00143	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—thyroid cancer	3.08e-05	0.00142	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—thyroid cancer	3.06e-05	0.00141	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—thyroid cancer	3.06e-05	0.00141	CcSEcCtD
Bosutinib—YES1—lymph node—thyroid cancer	3.02e-05	0.00124	CbGeAlD
Bosutinib—Renal failure—Doxorubicin—thyroid cancer	3.01e-05	0.00139	CcSEcCtD
Bosutinib—STK10—lymph node—thyroid cancer	2.99e-05	0.00123	CbGeAlD
Bosutinib—TAOK3—lymph node—thyroid cancer	2.98e-05	0.00123	CbGeAlD
Bosutinib—Hepatitis—Epirubicin—thyroid cancer	2.97e-05	0.00137	CcSEcCtD
Bosutinib—ABL1—head—thyroid cancer	2.94e-05	0.00121	CbGeAlD
Bosutinib—Urinary tract disorder—Epirubicin—thyroid cancer	2.93e-05	0.00135	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—thyroid cancer	2.93e-05	0.00135	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—thyroid cancer	2.92e-05	0.00135	CcSEcCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—thyroid cancer	2.91e-05	0.0357	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—thyroid cancer	2.91e-05	0.0357	CbGdCrCtD
Bosutinib—Urethral disorder—Epirubicin—thyroid cancer	2.91e-05	0.00134	CcSEcCtD
Bosutinib—SRC—lymph node—thyroid cancer	2.9e-05	0.0012	CbGeAlD
Bosutinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	2.9e-05	0.00134	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—thyroid cancer	2.86e-05	0.00132	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—thyroid cancer	2.81e-05	0.0013	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—thyroid cancer	2.77e-05	0.00128	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—thyroid cancer	2.76e-05	0.00127	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—thyroid cancer	2.75e-05	0.00127	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—thyroid cancer	2.72e-05	0.00125	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—thyroid cancer	2.71e-05	0.00125	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—thyroid cancer	2.7e-05	0.00125	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—thyroid cancer	2.7e-05	0.0331	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—thyroid cancer	2.7e-05	0.0331	CbGdCrCtD
Bosutinib—Urethral disorder—Doxorubicin—thyroid cancer	2.7e-05	0.00124	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—thyroid cancer	2.68e-05	0.00124	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—thyroid cancer	2.68e-05	0.00124	CcSEcCtD
Bosutinib—MAP2K5—lymph node—thyroid cancer	2.67e-05	0.0011	CbGeAlD
Bosutinib—CSF1R—lymph node—thyroid cancer	2.61e-05	0.00107	CbGeAlD
Bosutinib—Erythema multiforme—Doxorubicin—thyroid cancer	2.6e-05	0.0012	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—thyroid cancer	2.59e-05	0.00119	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—thyroid cancer	2.56e-05	0.00118	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—thyroid cancer	2.55e-05	0.00118	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—thyroid cancer	2.53e-05	0.00117	CcSEcCtD
Bosutinib—Back pain—Epirubicin—thyroid cancer	2.5e-05	0.00115	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—thyroid cancer	2.48e-05	0.00115	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—thyroid cancer	2.48e-05	0.00114	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—thyroid cancer	2.4e-05	0.00111	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—thyroid cancer	2.39e-05	0.0011	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—thyroid cancer	2.39e-05	0.0011	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—thyroid cancer	2.34e-05	0.00108	CcSEcCtD
Bosutinib—Malaise—Epirubicin—thyroid cancer	2.33e-05	0.00108	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—thyroid cancer	2.32e-05	0.00107	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—thyroid cancer	2.32e-05	0.00107	CcSEcCtD
Bosutinib—PDGFRB—lymph node—thyroid cancer	2.31e-05	0.000952	CbGeAlD
Bosutinib—Cough—Epirubicin—thyroid cancer	2.26e-05	0.00104	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—thyroid cancer	2.22e-05	0.00102	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—thyroid cancer	2.21e-05	0.00102	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—thyroid cancer	2.2e-05	0.00102	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—thyroid cancer	2.2e-05	0.00102	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—thyroid cancer	2.2e-05	0.00102	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	2.19e-05	0.00101	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—thyroid cancer	2.18e-05	0.001	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—thyroid cancer	2.16e-05	0.000996	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—thyroid cancer	2.14e-05	0.000989	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—thyroid cancer	2.13e-05	0.0262	CbGdCrCtD
Bosutinib—Oedema—Epirubicin—thyroid cancer	2.11e-05	0.000974	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—thyroid cancer	2.11e-05	0.000974	CcSEcCtD
Bosutinib—Infection—Epirubicin—thyroid cancer	2.1e-05	0.000968	CcSEcCtD
Bosutinib—Cough—Doxorubicin—thyroid cancer	2.09e-05	0.000964	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—thyroid cancer	2.07e-05	0.000955	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—thyroid cancer	2.07e-05	0.000954	CcSEcCtD
Bosutinib—ABL1—lymph node—thyroid cancer	2.06e-05	0.000849	CbGeAlD
Bosutinib—Skin disorder—Epirubicin—thyroid cancer	2.05e-05	0.000946	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—thyroid cancer	2.04e-05	0.00094	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—thyroid cancer	2.04e-05	0.00094	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—thyroid cancer	2.04e-05	0.00094	CcSEcCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	2.04e-05	0.025	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	2.04e-05	0.025	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—thyroid cancer	2.04e-05	0.025	CbGdCrCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	2.02e-05	0.000934	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—thyroid cancer	2.01e-05	0.000929	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—thyroid cancer	1.97e-05	0.0242	CbGdCrCtD
Bosutinib—Anaphylactic shock—Doxorubicin—thyroid cancer	1.95e-05	0.000901	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—thyroid cancer	1.95e-05	0.000901	CcSEcCtD
Bosutinib—Infection—Doxorubicin—thyroid cancer	1.94e-05	0.000896	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	1.92e-05	0.000888	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—thyroid cancer	1.92e-05	0.000884	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—thyroid cancer	1.91e-05	0.000883	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—thyroid cancer	1.9e-05	0.000876	CcSEcCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	1.88e-05	0.0231	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	1.88e-05	0.0231	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	1.88e-05	0.0231	CbGdCrCtD
Bosutinib—Dyspnoea—Epirubicin—thyroid cancer	1.88e-05	0.000869	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—thyroid cancer	1.84e-05	0.000847	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	1.82e-05	0.000841	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—thyroid cancer	1.82e-05	0.00084	CcSEcCtD
Bosutinib—Pain—Epirubicin—thyroid cancer	1.81e-05	0.000833	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	1.78e-05	0.000821	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—thyroid cancer	1.74e-05	0.000804	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—thyroid cancer	1.74e-05	0.000803	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—thyroid cancer	1.73e-05	0.000797	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—thyroid cancer	1.7e-05	0.000784	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	1.69e-05	0.000778	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—thyroid cancer	1.68e-05	0.000777	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—thyroid cancer	1.68e-05	0.000774	CcSEcCtD
Bosutinib—Pain—Doxorubicin—thyroid cancer	1.67e-05	0.000771	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—thyroid cancer	1.67e-05	0.00077	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—thyroid cancer	1.67e-05	0.00077	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—thyroid cancer	1.61e-05	0.000743	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	1.6e-05	0.000737	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—thyroid cancer	1.55e-05	0.000716	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—thyroid cancer	1.54e-05	0.000713	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—thyroid cancer	1.54e-05	0.000713	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—thyroid cancer	1.51e-05	0.000699	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—thyroid cancer	1.49e-05	0.000689	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—thyroid cancer	1.44e-05	0.000667	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—thyroid cancer	1.4e-05	0.000647	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—thyroid cancer	1.4e-05	0.000644	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—thyroid cancer	1.38e-05	0.000638	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—thyroid cancer	1.34e-05	0.000619	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—thyroid cancer	1.34e-05	0.000617	CcSEcCtD
Bosutinib—Rash—Epirubicin—thyroid cancer	1.33e-05	0.000614	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—thyroid cancer	1.33e-05	0.000614	CcSEcCtD
Bosutinib—Headache—Epirubicin—thyroid cancer	1.32e-05	0.00061	CcSEcCtD
Bosutinib—ABCB1—trachea—thyroid cancer	1.3e-05	0.000537	CbGeAlD
Bosutinib—Dizziness—Doxorubicin—thyroid cancer	1.29e-05	0.000596	CcSEcCtD
Bosutinib—Nausea—Epirubicin—thyroid cancer	1.25e-05	0.000579	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—thyroid cancer	1.24e-05	0.000573	CcSEcCtD
Bosutinib—Rash—Doxorubicin—thyroid cancer	1.23e-05	0.000568	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—thyroid cancer	1.23e-05	0.000568	CcSEcCtD
Bosutinib—Headache—Doxorubicin—thyroid cancer	1.22e-05	0.000565	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—thyroid cancer	1.16e-05	0.000535	CcSEcCtD
Bosutinib—ABCB1—thyroid gland—thyroid cancer	1.03e-05	0.000425	CbGeAlD
Bosutinib—ABCB1—head—thyroid cancer	9.15e-06	0.000377	CbGeAlD
Bosutinib—ABCB1—lymph node—thyroid cancer	6.41e-06	0.000264	CbGeAlD
Bosutinib—ERBB3—Disease—HRAS—thyroid cancer	3.87e-07	1.04e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—KRAS—thyroid cancer	3.86e-07	1.04e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—KRAS—thyroid cancer	3.86e-07	1.03e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HRAS—thyroid cancer	3.86e-07	1.03e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—BRAF—thyroid cancer	3.86e-07	1.03e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HRAS—thyroid cancer	3.85e-07	1.03e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NRAS—thyroid cancer	3.84e-07	1.03e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	3.84e-07	1.03e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	3.83e-07	1.03e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—NRAS—thyroid cancer	3.83e-07	1.03e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCND1—thyroid cancer	3.83e-07	1.03e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—PTEN—thyroid cancer	3.82e-07	1.02e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HIF1A—thyroid cancer	3.82e-07	1.02e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTEN—thyroid cancer	3.8e-07	1.02e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—BRAF—thyroid cancer	3.8e-07	1.02e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—HRAS—thyroid cancer	3.79e-07	1.02e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—AKT1—thyroid cancer	3.78e-07	1.01e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—thyroid cancer	3.78e-07	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—BRAF—thyroid cancer	3.78e-07	1.01e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCND1—thyroid cancer	3.77e-07	1.01e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—AKT1—thyroid cancer	3.75e-07	1.01e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—NRAS—thyroid cancer	3.75e-07	1e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—NRAS—thyroid cancer	3.73e-07	1e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HRAS—thyroid cancer	3.73e-07	9.99e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—thyroid cancer	3.72e-07	9.96e-06	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HRAS—thyroid cancer	3.71e-07	9.93e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NRAS—thyroid cancer	3.7e-07	9.92e-06	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—AKT1—thyroid cancer	3.7e-07	9.91e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—KRAS—thyroid cancer	3.7e-07	9.9e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PTEN—thyroid cancer	3.69e-07	9.9e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—NRAS—thyroid cancer	3.69e-07	9.89e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—HRAS—thyroid cancer	3.68e-07	9.86e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NRAS—thyroid cancer	3.67e-07	9.84e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—thyroid cancer	3.65e-07	9.77e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PTEN—thyroid cancer	3.64e-07	9.76e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NRAS—thyroid cancer	3.62e-07	9.71e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—KRAS—thyroid cancer	3.61e-07	9.69e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCND1—thyroid cancer	3.58e-07	9.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PTEN—thyroid cancer	3.57e-07	9.58e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—KRAS—thyroid cancer	3.56e-07	9.55e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HRAS—thyroid cancer	3.56e-07	9.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—AKT1—thyroid cancer	3.54e-07	9.48e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NRAS—thyroid cancer	3.53e-07	9.47e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TERT—thyroid cancer	3.53e-07	9.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—NRAS—thyroid cancer	3.49e-07	9.35e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HRAS—thyroid cancer	3.49e-07	9.35e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—KRAS—thyroid cancer	3.46e-07	9.27e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PTEN—thyroid cancer	3.46e-07	9.26e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PTEN—thyroid cancer	3.44e-07	9.23e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KRAS—thyroid cancer	3.43e-07	9.2e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HRAS—thyroid cancer	3.42e-07	9.16e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—AKT1—thyroid cancer	3.42e-07	9.15e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—AKT1—thyroid cancer	3.42e-07	9.15e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—AKT1—thyroid cancer	3.41e-07	9.13e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—NRAS—thyroid cancer	3.41e-07	9.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—AKT1—thyroid cancer	3.4e-07	9.1e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NRAS—thyroid cancer	3.39e-07	9.08e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HIF1A—thyroid cancer	3.38e-07	9.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KRAS—thyroid cancer	3.38e-07	9.05e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCND1—thyroid cancer	3.37e-07	9.03e-06	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—AKT1—thyroid cancer	3.35e-07	8.98e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KRAS—thyroid cancer	3.31e-07	8.86e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	3.31e-07	8.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTEN—thyroid cancer	3.3e-07	8.84e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NRAS—thyroid cancer	3.3e-07	8.83e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KRAS—thyroid cancer	3.3e-07	8.83e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—AKT1—thyroid cancer	3.29e-07	8.82e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HRAS—thyroid cancer	3.28e-07	8.8e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HRAS—thyroid cancer	3.28e-07	8.79e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—BRAF—thyroid cancer	3.28e-07	8.79e-06	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—AKT1—thyroid cancer	3.27e-07	8.77e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PTEN—thyroid cancer	3.25e-07	8.72e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NRAS—thyroid cancer	3.25e-07	8.71e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—AKT1—thyroid cancer	3.25e-07	8.7e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—thyroid cancer	3.23e-07	8.65e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—KRAS—thyroid cancer	3.23e-07	8.65e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—RXRA—thyroid cancer	3.22e-07	8.63e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—thyroid cancer	3.21e-07	8.61e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KRAS—thyroid cancer	3.21e-07	8.61e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NRAS—thyroid cancer	3.19e-07	8.54e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KRAS—thyroid cancer	3.19e-07	8.54e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PTEN—thyroid cancer	3.18e-07	8.52e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—KRAS—thyroid cancer	3.18e-07	8.51e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—thyroid cancer	3.17e-07	8.49e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—BRAF—thyroid cancer	3.16e-07	8.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KRAS—thyroid cancer	3.16e-07	8.47e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TPR—thyroid cancer	3.15e-07	8.45e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—thyroid cancer	3.14e-07	8.42e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—thyroid cancer	3.14e-07	8.41e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—thyroid cancer	3.12e-07	8.35e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	3.1e-07	8.32e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NRAS—thyroid cancer	3.08e-07	8.26e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—thyroid cancer	3.08e-07	8.25e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—thyroid cancer	3.07e-07	8.23e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—NRAS—thyroid cancer	3.07e-07	8.23e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—thyroid cancer	3.05e-07	8.17e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PTEN—thyroid cancer	3.05e-07	8.17e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—thyroid cancer	3.04e-07	8.15e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—thyroid cancer	3.03e-07	8.12e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—thyroid cancer	3.02e-07	8.08e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—thyroid cancer	3e-07	8.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—thyroid cancer	2.95e-07	7.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—NRAS—thyroid cancer	2.94e-07	7.89e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—thyroid cancer	2.94e-07	7.88e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	2.94e-07	7.87e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—thyroid cancer	2.94e-07	7.87e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—thyroid cancer	2.93e-07	7.86e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—thyroid cancer	2.92e-07	7.82e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—thyroid cancer	2.92e-07	7.82e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—thyroid cancer	2.9e-07	7.78e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—thyroid cancer	2.9e-07	7.77e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—thyroid cancer	2.9e-07	7.76e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—thyroid cancer	2.87e-07	7.7e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—thyroid cancer	2.87e-07	7.69e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTEN—thyroid cancer	2.84e-07	7.62e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—thyroid cancer	2.84e-07	7.6e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—thyroid cancer	2.84e-07	7.6e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—thyroid cancer	2.83e-07	7.59e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTEN—thyroid cancer	2.81e-07	7.54e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—thyroid cancer	2.81e-07	7.54e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	2.81e-07	7.53e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—thyroid cancer	2.81e-07	7.53e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—thyroid cancer	2.8e-07	7.51e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BRAF—thyroid cancer	2.8e-07	7.5e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—thyroid cancer	2.8e-07	7.5e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—thyroid cancer	2.77e-07	7.44e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—thyroid cancer	2.77e-07	7.43e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—thyroid cancer	2.77e-07	7.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—thyroid cancer	2.76e-07	7.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—thyroid cancer	2.74e-07	7.35e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—thyroid cancer	2.74e-07	7.35e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—thyroid cancer	2.73e-07	7.31e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—thyroid cancer	2.72e-07	7.29e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—thyroid cancer	2.72e-07	7.28e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—thyroid cancer	2.71e-07	7.27e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—thyroid cancer	2.71e-07	7.26e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—thyroid cancer	2.7e-07	7.24e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—thyroid cancer	2.69e-07	7.2e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—thyroid cancer	2.67e-07	7.17e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—thyroid cancer	2.67e-07	7.17e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—thyroid cancer	2.66e-07	7.13e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—thyroid cancer	2.65e-07	7.11e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—thyroid cancer	2.65e-07	7.1e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—thyroid cancer	2.64e-07	7.09e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—thyroid cancer	2.59e-07	6.95e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—thyroid cancer	2.59e-07	6.93e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—thyroid cancer	2.58e-07	6.9e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—thyroid cancer	2.55e-07	6.84e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—thyroid cancer	2.54e-07	6.8e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—thyroid cancer	2.53e-07	6.79e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—thyroid cancer	2.53e-07	6.79e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—thyroid cancer	2.52e-07	6.76e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—thyroid cancer	2.51e-07	6.73e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—thyroid cancer	2.5e-07	6.69e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—thyroid cancer	2.49e-07	6.68e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—thyroid cancer	2.49e-07	6.66e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—thyroid cancer	2.48e-07	6.65e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	2.48e-07	6.65e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—thyroid cancer	2.48e-07	6.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—thyroid cancer	2.48e-07	6.63e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—thyroid cancer	2.47e-07	6.63e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—thyroid cancer	2.44e-07	6.54e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—thyroid cancer	2.42e-07	6.49e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—thyroid cancer	2.42e-07	6.49e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—thyroid cancer	2.41e-07	6.46e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—thyroid cancer	2.41e-07	6.46e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—thyroid cancer	2.39e-07	6.42e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—thyroid cancer	2.39e-07	6.41e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—thyroid cancer	2.39e-07	6.39e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—thyroid cancer	2.38e-07	6.39e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—thyroid cancer	2.38e-07	6.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—thyroid cancer	2.37e-07	6.36e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—thyroid cancer	2.37e-07	6.35e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.36e-07	6.33e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—thyroid cancer	2.36e-07	6.32e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—thyroid cancer	2.34e-07	6.27e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—thyroid cancer	2.34e-07	6.27e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—thyroid cancer	2.33e-07	6.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—thyroid cancer	2.31e-07	6.19e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—thyroid cancer	2.31e-07	6.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—thyroid cancer	2.28e-07	6.12e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—thyroid cancer	2.26e-07	6.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—thyroid cancer	2.25e-07	6.04e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—thyroid cancer	2.25e-07	6.02e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—thyroid cancer	2.23e-07	5.97e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—thyroid cancer	2.22e-07	5.95e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—thyroid cancer	2.2e-07	5.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—thyroid cancer	2.19e-07	5.87e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—thyroid cancer	2.18e-07	5.85e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—thyroid cancer	2.16e-07	5.79e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—thyroid cancer	2.15e-07	5.77e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—thyroid cancer	2.13e-07	5.71e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—thyroid cancer	2.13e-07	5.71e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—thyroid cancer	2.12e-07	5.69e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—thyroid cancer	2.1e-07	5.63e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—thyroid cancer	2.09e-07	5.59e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—thyroid cancer	2.08e-07	5.56e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—thyroid cancer	2.06e-07	5.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—thyroid cancer	2.06e-07	5.52e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—thyroid cancer	2.05e-07	5.5e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—thyroid cancer	2.04e-07	5.47e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—thyroid cancer	2.04e-07	5.47e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—thyroid cancer	2.03e-07	5.45e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—thyroid cancer	1.99e-07	5.34e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—thyroid cancer	1.99e-07	5.33e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—thyroid cancer	1.99e-07	5.32e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—thyroid cancer	1.98e-07	5.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—RXRA—thyroid cancer	1.98e-07	5.32e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—thyroid cancer	1.97e-07	5.28e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—thyroid cancer	1.94e-07	5.2e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—thyroid cancer	1.9e-07	5.1e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—thyroid cancer	1.89e-07	5.07e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—thyroid cancer	1.87e-07	5.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—thyroid cancer	1.86e-07	4.97e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—thyroid cancer	1.85e-07	4.97e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—thyroid cancer	1.84e-07	4.92e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—thyroid cancer	1.83e-07	4.91e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—thyroid cancer	1.83e-07	4.89e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—thyroid cancer	1.82e-07	4.87e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—thyroid cancer	1.81e-07	4.85e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—thyroid cancer	1.77e-07	4.75e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—thyroid cancer	1.77e-07	4.75e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—thyroid cancer	1.76e-07	4.71e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—thyroid cancer	1.76e-07	4.71e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—thyroid cancer	1.75e-07	4.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—thyroid cancer	1.74e-07	4.65e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—thyroid cancer	1.71e-07	4.58e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—thyroid cancer	1.64e-07	4.39e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—thyroid cancer	1.62e-07	4.35e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—thyroid cancer	1.6e-07	4.29e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—thyroid cancer	1.6e-07	4.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—thyroid cancer	1.58e-07	4.23e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—thyroid cancer	1.57e-07	4.2e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—thyroid cancer	1.54e-07	4.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—thyroid cancer	1.53e-07	4.11e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—thyroid cancer	1.52e-07	4.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—thyroid cancer	1.51e-07	4.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—thyroid cancer	1.51e-07	4.04e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—thyroid cancer	1.45e-07	3.89e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—thyroid cancer	1.39e-07	3.74e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—thyroid cancer	1.35e-07	3.61e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—thyroid cancer	1.33e-07	3.57e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—thyroid cancer	1.29e-07	3.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—thyroid cancer	1.28e-07	3.44e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—thyroid cancer	1.25e-07	3.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—thyroid cancer	1.14e-07	3.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	9.85e-08	2.64e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—thyroid cancer	8.59e-08	2.3e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—thyroid cancer	8.04e-08	2.15e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—thyroid cancer	4.95e-08	1.33e-06	CbGpPWpGaD
